Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 4/2010

01-12-2010

Fracture risk assessment in postmenopausal women

Author: Ronald C. Hamdy

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2010

Login to get access

Abstract

Patients with osteoporosis have an increased risk of sustaining fractures because of the low bone mineral density (BMD) and altered bone micro-architecture which are characteristic features of the disease. Although a good correlation exists between BMD and fracture risks, many other factors influence this relationship. While there is consensus that patients with osteoporosis should be investigated and treated, the issue is much less clear for patients with osteopenia. Because osteopenia is so prevalent, it would be unrealistic to treat all patients with this condition. Therefore, there is a need to identify those patients who are at risk of sustaining a fracture and would benefit most from the available therapy. Providing treatment to the appropriate risk group would not only reduce the number of fractures, but could also reduce the adverse effects associated with treatment, as treating patients earlier could shorten the treatment time. The availability of tools to select patients at risk of fracture should change the impact of the disease.
Literature
1.
2.
Kanis JA, Melton LJ III, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefPubMed
3.
National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington DC: National Osteoporosis Foundation; 2008.
4.
Kanis JA, Johnell O, Oden A. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989–95.CrossRefPubMed
5.
Robbins JA, Schott AM, Garnero P, et al. Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int. 2005;16:149–54.CrossRefPubMed
6.
7.
Pluijm SM, Koes B, de Laet C, et al. A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies. J Bone Miner Res. 2009;24:768–74.CrossRefPubMed
8.
Diez-Perez A, Gonzàlez-Macias J, Marin F, et al. Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound. Osteoporos Int. 2007;18:629–39.CrossRefPubMed
9.
Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–39.CrossRefPubMed
10.
Ribot C, Temollieres F, Pouilles JM. Can we detect women with low bone mass using clinical risk factors? Am J Med. 1995;98(2A):52S–5.CrossRefPubMed
11.
Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5-year risk of hip fracture in postemenopausal women. JAMA. 2007;298:2389–98.CrossRefPubMed
12.
Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20:1813–9.CrossRefPubMed
13.
van Staa TP, Geusens P, Kanis JA, et al. A simple clinical score for estimating the long-term risk of fracture in postmenopausal women. QJM. 2006;99:673–82.CrossRefPubMed
14.
Kanis JA, Oden A, Johansson H, et al. FRAX and its application to clinical practice. Bone. 2009;44:732–43.CrossRef
15.
Piirtola M, Vahlberg T, Löppönen M, et al. Fractures as predictors of excess mortality in the aged-a population-based study with a 12-year follow up. Eur J Epidemiol. 2008;23:747–55.CrossRefPubMed
16.
Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513–21.CrossRefPubMed
17.
Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22:671–85.CrossRefPubMed
18.
Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–33.CrossRefPubMed
19.
Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137:1001–5.PubMed
20.
Wehren LE, Magaziner J. Hip fracture: risk factors and outcomes. Curr Osteoporos Rep. 2003;1:78–85.CrossRefPubMed
21.
Pande I, Scott DL, O’Neill TW, Pritchard C, et al. Quality of life, morbidity and mortality after low trauma hip fracture in men. Ann Rheum Dis. 2006;65:87–92.CrossRefPubMed
22.
Bass E, French DD, Bradham DD, et al. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol. 2007;17:514–9.CrossRefPubMed
23.
Davidson CW, Merilees MJ, Wilkinson TJ, et al. Hip fracture mortality and morbidity – can we do better? N Z Med J. 2001;114:329–32.PubMed
24.
Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320–3.CrossRefPubMed
25.
Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195–202.CrossRefPubMed
26.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–9.PubMed
27.
Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. 2000;15:183–7.CrossRefPubMed
28.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–45.CrossRefPubMed
29.
Melton LJ III, Ilstrup DM, Beckenbaugh RD, et al. Hip fracture recurrence. A population-based study. Clin Orthop Relat Res. 1982;167:131–8. Clin Ortho Res 1982;167:131.PubMed
30.
van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 2002;13:624.CrossRefPubMed
31.
Kanis JA, Johnell O, DeLaet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375–82.CrossRefPubMed
32.
Pongchaiyakul C, Nguyen ND, Jones G, et al. Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res. 2005;20:1349–55.CrossRefPubMed
33.
Siris ES, Bilezekian JP, Rubin MR, et al. Pins and plaster aren’t enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab. 2003;88:3482–6.CrossRefPubMed
34.
Bahl S, Coates PS, Greenspan SL. The management of osteoporosis following hip fracture: have we improved our care? Osteoporos Int. 2003;14:884–8.CrossRefPubMed
35.
Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003;14:722–7.CrossRefPubMed
36.
Lyles KW, Schenck AP, Colon-Emeric CS. Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents. Osteoporos Int. 2008;19:1225–33.CrossRefPubMed
37.
Tosi LL, Gliklich R, Kannan K, et al. The American Orthopaedic Association’s “own the bone” initiative to prevent secondary fractures. J Bone Joint Surg Am. 2008;90:163–73.CrossRefPubMed
38.
Gregory JS, Aspden RM. Femoral geometry as a risk factor for osteoporotic hip fracture in men and women. Med Eng Phys. 2008;30:1275–86.CrossRefPubMed
39.
Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531–8.CrossRefPubMed
40.
Johnell O, Oden A, DeLaet C, et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int. 2002;13:523–6.CrossRefPubMed
41.
Delmas PD, Eastell R, Garnero P, et al. Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(Suppl 6):S2–17.CrossRefPubMed
42.
DeLaet CE, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res. 1998;13:1587–93.CrossRef
43.
DeLaet CE, Van der Klift M, Hofman A, et al. Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res. 2002;17:2231–6.CrossRef
44.
Hochberg MC. Racial differences in bone strength. Trans Am Clin Climatol Assoc. 2007;118:305–15.PubMed
45.
Kanis JA, Borstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporosis Int. 2005;16:581–9.CrossRef
46.
LaFleur J, McAdam-Marx C, Kirkness C, et al. Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature. Ann Pharmacother. 2008;42(3):375–86.CrossRefPubMed
47.
DeLaet C, Kanis JA, Ogden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330–8.CrossRef
48.
Papaioannou A, Kennedy CC, Cranney A, et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int. 2009;20:507–18.CrossRefPubMed
49.
Waugh EJ, Lam MA, Hawker GA, et al. Risk factors for low bone mass in healthy 40–60 year old women: a systematic review of the literature. Osteoporos Int. 2009;20:1–21.CrossRefPubMed
50.
Stolee P, Poss J, Cook RJ, et al. Risk factors for hip fracture in older home care clients. J Gerontol A Biol Med Sci. 2009;64:403–10.
51.
52.
Lim LS, Fink Ha, Kuskowski MA, et al. Osteoporotic fractures in men (MrOS) study group. Loop diuretic use and increased rates of hip bone loss in older men: the osteoporotic fractures in men study. Arch Intern Med. 2008;168:735–40.CrossRefPubMed
53.
Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav. 2004;5(Suppl 2):S3–15.CrossRefPubMed
54.
Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.CrossRefPubMed
55.
Hamdy RC, Kiebzak GM. Variance in 10-year fracture irsk calculated with and without T-scores in select subgroups of normal and osteoporotic patients. J Clin Densitom. 2009;12:158–61.CrossRefPubMed
56.
Hamdy RC. FRAX®: a fracture risk assessment tool. Aging Health. 2009;5:489–494.
57.
Borgström F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int. 2006;17:1459–71.CrossRefPubMed
58.
Dawson-Hughes B, Tosteson AN, Melton LJ III, et al. National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449–58.CrossRefPubMed
59.
Tosteson AN, Melton LJ III, Dawson-Hughes B, et al. National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437–47.CrossRefPubMed
Metadata
Title
Fracture risk assessment in postmenopausal women
Author
Ronald C. Hamdy
Publication date
01-12-2010
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2010
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-009-9118-4

Other articles of this Issue 4/2010

Reviews in Endocrine and Metabolic Disorders 4/2010 Go to the issue

OriginalPaper

Diagnosis and treatment of osteopenia

OriginalPaper

Monitoring pharmacological therapy for osteoporosis

OriginalPaper

SERMs and SERMs with estrogen for postmenopausal osteoporosis

OriginalPaper

Compliance and persistence with osteoporosis medications: A critical review of the literature

EditorialNotes

Special edition update on postmenopausal osteoporosis

OriginalPaper

Cellular mechanisms of bone remodeling
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits